Oren Hershkovitz
Chief Executive Officer at ENLIVEX THERAPEUTICS LTD.
Net worth: 27 778 $ as of 30/04/2024
Oren Hershkovitz active positions
Companies | Position | Start | End |
---|---|---|---|
ENLIVEX THERAPEUTICS LTD. | Chief Executive Officer | 16/11/2019 | - |
OPKO Biologics Ltd.
OPKO Biologics Ltd. Pharmaceuticals: MajorHealth Technology OPKO Biologics Ltd. develops next-generation, bio-better, long-acting versions of therapeutic proteins and peptide drugs. Its products include Human Growth Hormone, Glucagon dual receptor agonist, Factor VIIa and Factor IX for Hemophilia, Anti-Obesity Peptide Oxyntomodulin, Interferon and Erythropoietin, and Atherosclerosis and Rheumatoid Arthritis long-acting therapies. The company was founded by Novik A. Shai on August 22, 2003 and is headquartered in Nes Ziona, Israel. | Director/Board Member | 01/09/2016 | - |
Career history of Oren Hershkovitz
Training of Oren Hershkovitz
Ben-Gurion University of the Negev | Doctorate Degree |
Statistics
International
Israel | 4 |
Operational
Chief Executive Officer | 1 |
Director/Board Member | 1 |
Doctorate Degree | 1 |
Sectoral
Health Technology | 3 |
Consumer Services | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
Listed companies | 1 |
---|---|
ENLIVEX THERAPEUTICS LTD. | Health Technology |
Private companies | 1 |
---|---|
OPKO Biologics Ltd.
OPKO Biologics Ltd. Pharmaceuticals: MajorHealth Technology OPKO Biologics Ltd. develops next-generation, bio-better, long-acting versions of therapeutic proteins and peptide drugs. Its products include Human Growth Hormone, Glucagon dual receptor agonist, Factor VIIa and Factor IX for Hemophilia, Anti-Obesity Peptide Oxyntomodulin, Interferon and Erythropoietin, and Atherosclerosis and Rheumatoid Arthritis long-acting therapies. The company was founded by Novik A. Shai on August 22, 2003 and is headquartered in Nes Ziona, Israel. | Health Technology |
- Stock Market
- Insiders
- Oren Hershkovitz
- Experience